---
stepsCompleted:
  - step-01-document-discovery
  - step-02-prd-analysis
  - step-03-epic-coverage-validation
  - step-04-ux-alignment
  - step-05-epic-quality-review
  - step-06-final-assessment
assessmentDate: "2026-04-05"
project_name: pharma_RD_workflow
documentsForAssessment:
  prd: _bmad-output/planning-artifacts/prd.md
  architecture: _bmad-output/planning-artifacts/architecture.md
  epics: _bmad-output/planning-artifacts/epics.md
  ux: null
assessor: Implementation Readiness workflow (automated)
---

# Implementation Readiness Assessment Report

**Date:** 2026-04-05  
**Project:** pharma_RD_workflow

## Document Discovery (Step 1 — complete)

### PRD documents

**Whole documents:**

- `prd.md` (29,239 bytes, modified 2026-04-04)

**Sharded documents:** none found (`*prd*/index.md` pattern)

### Architecture documents

**Whole documents:**

- `architecture.md` (23,341 bytes, modified 2026-04-04)

**Sharded documents:** none found

### Epics and stories

**Whole documents:**

- `epics.md` (38,972 bytes, modified 2026-04-05)

**Sharded documents:** none found

### UX design documents

**Whole documents:** none matching `*ux*.md`

**Sharded documents:** none found (`*ux*/index.md` pattern)

### Other planning artifacts (not in required set)

- `product-brief-pharma_RD_workflow.md` (10,113 bytes, modified 2026-04-04)
- Prior readiness reports: `implementation-readiness-report-2026-04-04.md`, `implementation-readiness-report-2026-04-06.md`

### Critical issues

**Duplicates:** none — no whole-and-sharded pairs for the same document type.

**Missing (warning):**

- No standalone UX design document found under the prescribed patterns in `{planning_artifacts}`. Addressed further under **UX Alignment Assessment**.

---

## PRD Analysis

### Functional Requirements

**FR1:** Workflow operator can start a full **pipeline run** on demand.

**FR2:** Workflow operator can configure a **recurring schedule** for pipeline runs (default: weekly).

**FR3:** System can execute agent stages in the **required order** with defined **handoffs** between stages.

**FR4:** System can **persist** intermediate outputs between stages for a given run identifier.

**FR5:** System can associate all stage outputs with a **single run** (correlation) for traceability and demo.

**FR6:** Clinical Data Agent can **discover and summarize** new or updated **clinical trial publications** relevant to configured therapeutic areas.

**FR7:** Clinical Data Agent can ingest **internal research summaries** when supplied via configured inputs (including **stub/sample** data for practice).

**FR8:** Competitor Intelligence Agent can track **competitor product approvals** and material **regulatory disclosures** for configured competitors.

**FR9:** Competitor Intelligence Agent can track **pipeline disclosures** relevant to configured watch scopes.

**FR10:** Competitor Intelligence Agent can **flag** significant **patent filing** activity for configured competitors.

**FR11:** Consumer Insight Agent can process **consumer feedback** signals from configured sources (public/mock as scoped).

**FR12:** Consumer Insight Agent can incorporate **pharmacy sales trend** signals when those feeds are configured and available.

**FR13:** Consumer Insight Agent can surface **unmet need / demand** signals from configured market sources.

**FR14:** Synthesis Agent can **consume** the structured outputs of the Clinical, Competitor, and Consumer agents for a run.

**FR15:** Synthesis Agent can **cross-reference** signals across domains to produce a **ranked list** of formulation or line-extension **opportunities**.

**FR16:** For each ranked item, Synthesis Agent can attach **supporting evidence** references suitable for **human verification**.

**FR17:** For each ranked item, Synthesis Agent can provide a **commercial viability** assessment section (qualitative in MVP unless otherwise specified).

**FR18:** Delivery Agent can **render** a **structured insight report** for a completed run.

**FR19:** Delivery Agent can **distribute** the report to configured **R&D scientist** and **marketing lead** recipients (channel: email, file drop, or in-app viewer—implementation open).

**FR20:** R&D scientist can **open and read** the structured insight report for a given run.

**FR21:** Marketing lead can **open and read** the same structured insight report for a given run.

**FR22:** Report presentation can make clear that items are **recommendations** and that **pursuit decisions** remain **human-owned**.

**FR23:** Workflow operator can configure **therapeutic area scope** and boundaries for monitoring.

**FR24:** Workflow operator can configure **competitor watchlists** and related keywords or identifiers.

**FR25:** Workflow operator can configure **connection settings** for external data sources permitted in the deployment (public APIs, files, stubs).

**FR26:** System can operate in a **practice** mode using **public and/or mock** sources without requiring enterprise SSO.

**FR27:** Structured report can state when **little net-new signal** was found versus material changes.

**FR28:** Structured report can summarize **what was scanned** (sources/scopes) for the run at a high level.

**FR29:** Workflow operator can view **per-agent status** for an execution.

**FR30:** Workflow operator can **retry** a failed stage when supported without manually re-creating upstream artifacts.

**FR31:** System can emit **run history** and logs sufficient to produce a **demonstration recording** of agent execution and final delivery.

**FR32:** Organization can **restrict access** to reports to **authorized** users or distribution lists (exact mechanism implementation-open; may be coarse in practice builds).

**FR33:** *(Phase 2)* System can **alert** stakeholders to major external events between scheduled runs.

**FR34:** *(Phase 2)* Admin can integrate **enterprise SSO** and centralized **secrets** management for connectors.

**FR35:** *(Phase 3)* System can support **enterprise** audit, PHI-aware feeds, and **multi-tenant** isolation where productized.

**Total FRs:** 35 (FR1–FR32 MVP contract; FR33–FR35 explicitly phased in PRD).

### Non-Functional Requirements

**NFR-P1:** A full scheduled pipeline run (all five stages through delivery) completes within a **predictable window** suitable for a **recorded demo** (target: **under 60 minutes wall-clock** for MVP configuration on practice data; configurable timeout per stage).

**NFR-P2:** Recipients can open and read a delivered report on typical corporate hardware without **specialized** client software (browser or standard email/PDF—implementation open).

**NFR-P3:** External source calls use **timeouts** and **bounded retries** so one slow feed does not block the entire run indefinitely without operator visibility.

**NFR-S1:** Secrets (API keys, tokens) are **not** stored in source control; they are injected via **environment** or **secrets** mechanism appropriate to deployment.

**NFR-S2:** Report artifacts and logs are **access-controlled** to authorized roles/distribution lists (see FR32).

**NFR-S3:** Data in transit between components and external APIs uses **TLS** where APIs support it.

**NFR-S4:** MVP assumes **no PHI** in prompts/logs; if PHI is later in scope, processing must follow an **approved** privacy design (out of MVP—see Domain Requirements).

**NFR-R1:** Failed stages are **visible** to the workflow operator with **actionable** error summaries (not silent failure).

**NFR-R2:** Run history is **durable** enough to answer “what ran, when, and what failed” for **demo** and **debug** (minimum retention: configurable; default **30 days** for practice unless otherwise set).

**NFR-R3:** Idempotent or safe **retry** semantics for stage reruns where FR30 applies (no duplicate conflicting artifacts without clear versioning).

**NFR-I1:** Connectors declare **expected** data formats and **degrade gracefully** when a source returns empty or partial data (report still generated with transparency per FR27–FR28).

**NFR-I2:** Integration failures are **classified** (auth, rate limit, schema change, network) in logs to shorten operator time-to-fix.

**NFR-O1:** Each run emits a **correlation identifier** propagated across stages (aligns with FR5).

**NFR-O2:** Structured logs contain **stage name**, **start/end**, and **outcome** suitable for **Loom**-style narration.

**Total NFRs:** 14 (labeled NFR-P1 through NFR-O2 in PRD).

### Additional requirements and constraints

- **Domain-specific:** Decision-support positioning (not SaMD diagnosis/treatment in MVP); human oversight; future HIPAA/PHI, data residency, evidence traceability, security baseline, model/prompt governance (enterprise).
- **Integrations (MVP/Growth):** Public connectors + stubs; growth SSO, CRM, lakes, etc.
- **Risk mitigations:** Citations, confidence labeling, access control, PHI redaction policies (table in PRD).
- **SaaS B2B:** Orchestration-first, RBAC table, single-tenant practice vs future multi-tenant, compliance cross-references.
- **Inputs & traceability:** Links `product-brief` and brainstorming themes to PRD sections.

### PRD completeness assessment

The PRD is **complete for implementation planning**: numbered FRs and NFRs are testable, scoped into MVP vs phased (FR33–FR35), and supported by user journeys, domain notes, and a traceability table. Wording is consistent with architecture and epics documents.

---

## Epic Coverage Validation

### Epic FR coverage extracted (from `epics.md`)

| FR | Epic(s) (per FR Coverage Map) |
|----|--------------------------------|
| FR1 | Epic 1 |
| FR2 | Epic 2 |
| FR3 | Epic 1 |
| FR4 | Epic 1 |
| FR5 | Epic 1 |
| FR6–FR7 | Epic 3 |
| FR8–FR10 | Epic 4 |
| FR11–FR13 | Epic 5 |
| FR14–FR17 | Epic 6 |
| FR27–FR28 | Epic 6 |
| FR18–FR22 | Epic 7 |
| FR23–FR26 | Epic 8 |
| FR29 | Epic 1 (+ Epic 2 for failure states) |
| FR30 | Epic 2 |
| FR31 | Epic 1, 7 |
| FR32 | Epic 8 |
| FR33–FR35 | — (roadmap / out of MVP) |

### Coverage matrix (summary)

For **FR1–FR32** (MVP), each requirement appears in the epics **FR Coverage Map** and is backed by stories **1.1–8.5** (plus LLM enhancement stories **3.3, 4.4, 5.4, 6.5, 7.6** where applicable). **FR33–FR35** are intentionally **not** mapped to MVP stories; the epics document lists them under **Roadmap (not in MVP contract)**, matching the PRD’s phased wording.

| FR | Status |
|----|--------|
| FR1–FR32 | Covered in epics (traceable to epic list and stories) |
| FR33–FR35 | Explicitly deferred — **aligned** with PRD post-MVP / phased FRs |

### Missing FR coverage (MVP)

**None.** All MVP FRs (FR1–FR32) have a declared epic mapping and story decomposition.

### Coverage statistics

- **Total PRD FRs:** 35  
- **MVP FRs (FR1–FR32):** 32 — **32 covered** in epics (100%)  
- **Phased FRs (FR33–FR35):** 3 — **documented as roadmap**, not MVP gaps  

---

## UX Alignment Assessment

### UX document status

**Not found:** No standalone `{planning_artifacts}/*ux*.md` or sharded `*ux*/index.md`.

**Recorded in epics:** `epics.md` states there is **no UX design specification** under planning artifacts; report consumption may use **email**, **file drop**, or a **minimal static viewer** per PRD (Epic 7).

### Alignment issues

- **PRD ↔ Architecture:** Both assume a **thin consumption surface** (structured report artifact, email/file/optional viewer, CLI/API trigger). Architecture explicitly notes **no UX spec loaded** and defers rich SPA until a UX spec exists — **consistent** with the PRD’s journey-driven “structured report UX” without mandating a separate UX file.
- **PRD ↔ Epics:** Journeys 1–3 and the journey summary table are reflected in Epic 6–7 stories (rankings, evidence, quiet-run transparency, human-owned pursuit language).

### Warnings

- **Low severity:** If the team later wants pixel-level UI specs or a marketing site, add a **UX specification** artifact; until then, acceptance criteria in Epic 7 stories are the effective UX contract for MVP.

---

## Epic Quality Review (create-epics-and-stories alignment)

### Checklist summary

| Criterion | Assessment |
|-----------|------------|
| Epics deliver user / operator value | **Pass** — Epics are framed around operators, scientists, marketing, admins; Epic 1 establishes a runnable pipeline (demo value), not “database only.” |
| Epic independence (no Epic N → N+1 hard requirement) | **Pass** — Documented order Epic 1 → 2; 3–5 on contracts; 6 → 7; Epic 8 parallelizable early. No epic requires a *future* epic to *start* (only natural pipeline ordering). |
| Story sizing & BDD-style ACs | **Pass** — Stories use Given/When/Then; FR traceability on key stories. |
| Forward dependencies | **Pass** — Within-epic sequencing is backward-only (e.g. 1.2 after 1.1). |
| Tables / persistence timing | **Pass** — Story 1.2 introduces SQLite when persistence is needed (not a one-shot full schema dump unrelated to stories). |
| Starter template / greenfield | **Pass** — Story 1.1 matches architecture (`uv`, Python 3.12, CI). |

### Violations by severity

- **Critical:** none observed.  
- **Major:** none observed.  
- **Minor:** Epic 1 includes inherently **scaffold** work (Story 1.1); this is **appropriate for greenfield** and matches Step 5’s “initial project setup story” expectation — not logged as a defect.

---

## Summary and Recommendations

### Overall readiness status

**READY** — PRD, architecture, and epics are **aligned**; **MVP FR coverage is complete**; gaps are **documented** (standalone UX artifact optional; FR33–FR35 roadmap).

### Critical issues requiring immediate action

- **None** for starting Phase 4 implementation against the current MVP scope.

### Recommended next steps

1. **Proceed** with sprint execution using `epics.md` and implementation-artifact specs for GPT extension stories (3.3, 4.4, 5.4, 6.5, 7.6) in the documented order after baseline MVP.  
2. **Optionally** add a lightweight `ux.md` (or sharded UX folder) if stakeholders need a single UX source of truth beyond PRD journeys + Epic 7 ACs.  
3. **Track** FR33–FR35 on the product roadmap with explicit discovery before enterprise claims.

### Final note

This assessment identified **no blocking gaps** for MVP traceability; **one planning warning** (no standalone UX file) is **mitigated** by PRD + architecture + Epic 7. You may proceed to implementation or tighten UX documentation first based on stakeholder needs.

---

**Report path:** `_bmad-output/planning-artifacts/implementation-readiness-report-2026-04-05.md`
